

GLOBAL MARKETS FOR BIOENGINEERED PROTEIN DRUGS



BIO009G
January 2017

Shalini Shahani Dewan
Project Analyst

ISBN: 1-62296-417-9



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
info@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THIS STUDY	2
CONTRIBUTIONS OF THE STUDY AND FOR WHOM	3
SCOPE OF THE STUDY	3
METHODOLOGY	3
INFORMATION SOURCES	4
ANALYST'S CREDENTIALS	4
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	5
DISCLAIMER	5
CHAPTER 2 EXECUTIVE SUMMARY	7
<i>SUMMARY TABLE GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY REGION, 2014-2021 (\$ MILLIONS)</i>	8
CHAPTER 3 OVERVIEW	10
BIOSYNTHESIS OF PROTEINS	10
TRANSCRIPTION	10
TRANSLATION	11
POST-TRANSLATIONAL MODIFICATION	11
BIOENGINEERED PROTEIN DRUGS	11
<i>TABLE 1 BIOENGINEERED PROTEIN DRUGS VS. CHEMICALLY SYNTHESIZED DRUGS</i>	12
HISTORY OF BIOENGINEERED PROTEIN DRUGS	13
<i>TABLE 2 EVOLUTION OF BIOENGINEERED PROTEIN DRUGS</i>	13
ADVANTAGES OF BIOENGINEERED PROTEIN DRUGS	14
MANUFACTURING TECHNOLOGY	15
FRACTIONATION/COHN'S METHOD	15
<i>TABLE 3 PROTEIN DRUGS MADE BY FRACTIONATION</i>	16
MICROBIAL/FERMENTATION PROCESS	16
<i>TABLE 4 THERAPEUTIC DRUGS PRODUCED BY MICROBIAL FERMENTATION</i>	17
GENETIC ENGINEERING	17
GENETICALLY MODIFIED ORGANISMS	18
PHARMING	18
<i>TABLE 5 PROTEIN DRUGS PRODUCED BY TRANSGENIC ANIMALS, PLANTS AND MICROORGANISMS</i>	18
MAMMALIAN CELL CULTURE	19
<i>TABLE 6 PROTEIN DRUGS MADE BY MAMMALIAN CELL CULTURE</i>	19
ADMINISTRATION TECHNOLOGIES OF BIOENGINEERED PROTEIN DRUGS	20
USE OF DRUG DELIVERY SYSTEMS IN CURRENT MEDICAL APPROACHES	20
TRADITIONAL METHODS OF DRUG DELIVERY	20
Oral	20
Topical	21
Trans mucosal	21

TOPIC	PAGE NO.
Inhalation	21
Parenteral	21
TABLE 7 ROUTES OF DRUG DELIVERY	21
Limitations Encountered by Traditional Drug Delivery	22
MOLECULAR CLASSIFICATION	22
MONOCLONAL ANTIBODIES	22
CYTOKINES	23
Interferons	23
Interleukins	24
Colony Stimulating Factors	24
PEPTIDE HORMONES	24
Follicle Stimulating Hormone and Luteinizing Hormone	25
Growth Hormones	25
Erythropoietin	25
Insulin	25
BLOOD PRODUCTS	26
Alpha 1-Protease Inhibitor	26
Anti-Hemophilic Factor	26
Anti-Thrombin	26
C1-Esterase Inhibitor	27
Coagulation Factors	27
Immunoglobulins	27
Protein C	28
Thrombin	28
PEPTIDE ANTIBIOTICS	28
VACCINES	28
THERAPEUTIC ENZYMES	29
CHAPTER 4 REGULATORY ASPECTS	32
MONOCLONAL ANTIBODIES	32
TABLE 8 NEW APPROVALS OF MONOCLONAL ANTIBODIES (FROM 2014-MAY 2016)	32
CYTOKINES	33
TABLE 9 NEW APPROVALS OF CYTOKINES (FROM 2014-2015)*	34
VACCINES	34
TABLE 10 NEW APPROVALS IN VACCINES (FROM 2014-MAY 2016)	34
PEPTIDE HORMONES	35
TABLE 11 NEW APPROVALS IN PEPTIDE HORMONES (FROM 2014-2015)*	35
THERAPUETIC ENZYMES	36
TABLE 12 NEW APPROVALS IN THERAPEUTIC ENZYMES (FROM 2014-2015)*	36
BLOOD PRODUCTS	36
TABLE 13 NEW APPROVALS IN BLOOD PRODUCTS (FROM 2014-MAY 2016)	36
PEPTIDE ANTIBIOTICS	37
TABLE 14 NEW APPROVALS IN PEPTIDE ANTIBIOTICS (FROM 2014-2015)*	37
RECALLS	38
TABLE 15 RECALLS (FROM 2014-2015)*	38
SAFETY ALERTS	39
TABLE 16 SAFETY ALERTS (FROM 2014-2015)*	39

TOPIC	PAGE NO.
CHAPTER 5 NEW DEVELOPMENTS	42
MONOCLONAL ANTIBODIES	42
<i>TABLE 17 PIPELINE PRODUCTS OF MONOCLONAL ANTIBODIES</i>	42
VACCINES	47
<i>TABLE 18 PIPELINE PRODUCTS OF VACCINES</i>	48
CYTOKINES	50
<i>TABLE 19 PIPELINE PRODUCTS OF CYTOKINES</i>	50
PEPTIDE HORMONES	50
<i>TABLE 20 PIPELINE PRODUCTS OF PEPTIDE HORMONES</i>	51
PEPTIDE ANTIBIOTICS	51
<i>TABLE 21 PIPELINES PRODUCTS OF PEPTIDE ANTIBIOTICS</i>	52
THERAPUETIC ENZYMES	52
<i>TABLE 22 PIPELINE PRODUCTS OF THERAPUETIC ENZYMES</i>	53
BLOOD PRODUCTS	53
<i>TABLE 23 PIPELINE PRODUCTS OF BLOOD PRODUCTS</i>	53
MERGERS AND ACQUISITIONS	54
<i>TABLE 24 MERGERS AND ACQUISITIONS OF TOP PHARMACEUTICAL COMPANIES</i>	54
CHAPTER 6 MARKET ANALYSIS BY TYPE	58
MARKET BY TYPE	58
MARKET OVERVIEW	59
MARKET REVENUE	59
<i>TABLE 25 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, THROUGH 2021 (\$ MILLIONS)</i>	60
<i>FIGURE 1 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, 2014-2021 (\$ MILLIONS)</i>	60
MARKET SHARE	61
<i>TABLE 26 GLOBAL MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, 2015 (%)</i>	61
<i>FIGURE 2 GLOBAL MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, 2015 (%)</i>	61
PEPTIDE HORMONES	62
Market Overview	63
Market Revenue	64
<i>TABLE 27 GLOBAL MARKET FOR PEPTIDE HORMONES, BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	64
<i>FIGURE 3 GLOBAL MARKET FOR PEPTIDE HORMONES, BY REGION, 2014-2021 (\$ MILLIONS)</i>	64
VACCINES	65
Market Overview	66
Market Revenue	66
<i>TABLE 28 GLOBAL MARKET FOR VACCINES, BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	67
<i>FIGURE 4 GLOBAL MARKET FOR VACCINES, BY REGION, 2014-2021 (\$ MILLIONS)</i>	67
THERAPEUTIC ENZYMES	68
Market Overview	68
Market Revenue	69

TOPIC	PAGE NO.
<i>TABLE 29 GLOBAL MARKET FOR THERAPEUTIC ENZYMES, BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	69
<i>FIGURE 5 GLOBAL MARKET FOR THERAPEUTIC ENZYMES, BY REGION, 2014-2021 (\$ MILLIONS)</i>	70
MONOCLONAL ANTIBODIES	70
Market Overview	70
Market Revenue	71
<i>TABLE 30 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	72
<i>FIGURE 6 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2014-2021 (\$ MILLIONS)</i>	72
CYTOKINES	72
Market Overview	73
Market Revenue	73
<i>TABLE 31 GLOBAL MARKET FOR CYTOKINES, BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	74
<i>FIGURE 7 GLOBAL MARKET FOR CYTOKINES, BY REGION, 2014-2021 (\$ MILLIONS)</i>	74
BLOOD PRODUCTS AND PEPTIDE ANTIBIOTICS	74
Market Overview	75
Market Revenue	76
<i>TABLE 32 GLOBAL MARKET FOR BLOOD FACTORS AND PEPTIDE ANTIBIOTICS, BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	77
<i>FIGURE 8 GLOBAL MARKET FOR BLOOD FACTORS AND PEPTIDE ANTIBIOTICS, BY REGION, 2014-2021 (\$ MILLIONS)</i>	77
CHAPTER 7 INDUSTRY STRUCTURE	79
PEPTIDE HORMONES	79
MARKET LEADERS	79
<i>TABLE 33 LEADING MANUFACTURERS/SUPPLIERS OF PEPTIDE HORMONES, 2015</i>	79
MARKET SHARE	81
<i>TABLE 34 GLOBAL MARKET SHARE OF MANUFACTURERS AND SUPPLIERS FOR BIOENGINEERED PEPTIDE HORMONES, 2015 (%)</i>	81
<i>FIGURE 9 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR BIOENGINEERED PEPTIDE HORMONES, 2015 (%)</i>	82
VACCINES	82
MARKET LEADERS	82
<i>TABLE 35 LEADING MANUFACTURERS/SUPPLIERS OF VACCINES, 2015</i>	82
MARKET SHARE	85
<i>TABLE 36 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR VACCINES, 2015 (%)</i>	86
<i>FIGURE 10 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR VACCINES, 2015 (%)</i>	86
THERAPEUTIC ENZYMES	86
MARKET LEADERS	86
<i>TABLE 37 LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC ENZYMES, 2015</i>	86
MARKET SHARE	87
<i>TABLE 38 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR THERAPEUTIC ENZYMES, 2015 (%)</i>	88

TOPIC	PAGE NO.
<i>FIGURE 11 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR THERAPEUTIC ENZYMES, 2015 (%)</i>	88
MONOCLONAL ANTIBODIES	89
MARKET LEADERS	89
<i>TABLE 39 LEADING MANUFACTURERS/SUPPLIERS OF MONOCLONAL ANTIBODIES, 2015</i>	89
MARKET SHARE	90
<i>TABLE 40 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR MONOCLONAL ANTIBODIES, 2015 (%)</i>	90
<i>FIGURE 12 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR MONOCLONAL ANTIBODIES, 2015 (%)</i>	91
CYTOKINES	91
MARKET LEADERS	91
<i>TABLE 41 LEADING MANUFACTURERS/SUPPLIERS OF CYTOKINES, 2015</i>	91
MARKET SHARE	92
<i>TABLE 42 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR CYTOKINE, 2015 (%)</i>	92
<i>FIGURE 13 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR CYTOKINE, 2015 (%)</i>	92
BLOOD FACTORS	93
MARKET LEADERS	93
<i>TABLE 43 LEADING MANUFACTURERS/SUPPLIERS OF RECOMBINANT BLOOD PRODUCTS, 2015</i>	93
MARKET SHARE	94
<i>TABLE 44 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR RECOMBINANT BLOOD PRODUCTS, 2015 (%)</i>	94
<i>FIGURE 14 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR RECOMBINANT BLOOD PRODUCTS, 2015 (%)</i>	94
PEPTIDE ANTIBIOTICS	95
MARKET LEADERS	95
<i>TABLE 45 LEADING MANUFACTURERS/SUPPLIERS OF PEPTIDE ANTIBIOTICS, 2015</i>	95
MARKET SHARE	96
<i>TABLE 46 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR PEPTIDE ANTIBIOTICS, 2015 (%)</i>	96
<i>FIGURE 15 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR PEPTIDE ANTIBIOTICS, 2015 (%)</i>	96
CHAPTER 8 MARKET BY DISEASE	99
MARKET BY DISEASE	99
MARKET OVERVIEW	99
MARKET REVENUE	100
<i>TABLE 47 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, THROUGH 2021 (\$ MILLIONS)</i>	101
<i>FIGURE 16 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, 2014-2021 (\$ MILLIONS)</i>	101
MARKET SHARE	101
<i>TABLE 48 GLOBAL MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, 2015</i>	102
<i>FIGURE 17 GLOBAL MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, 2015 (%)</i>	102

TOPIC	PAGE NO.
DIABETES	102
Type 1 Diabetes	103
Type 2 Diabetes	103
Gestational Diabetes	103
Market Overview	104
Market Revenue	104
<i>TABLE 49 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR DIABETES, BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	105
<i>FIGURE 18 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR DIABETES, BY REGION, 2014-2021 (\$ MILLIONS)</i>	105
CANCER	106
<i>TABLE 50 VARIOUS CANCER TYPES DEPENDING ON THE TISSUE OF ORIGIN</i>	107
<i>TABLE 51 CATEGORIES OF CANCER</i>	107
Market Overview	108
Market Revenue	109
<i>TABLE 52 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR CANCER, BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	109
<i>FIGURE 19 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR CANCER, BY REGION, 2014-2021 (\$ MILLIONS)</i>	109
BLOOD DISORDERS AND SKIN DISEASES	110
Blood Disorders	110
Bleeding Disorders	111
Anemia	111
Leukemia	112
Multiple Myeloma	112
Skin Diseases	113
Skin and Skin structure Infections (SSSI)	113
Complicated Skin and Skin structure Infection (cSSSI)	113
Uncomplicated Skin and Skin structure Infection (uSSSI)	113
Clostridium difficile (C. difficile)	114
Market Overview	114
Market Revenue	115
<i>TABLE 53 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR BLOOD DISORDERS AND SKIN DISEASES, BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	116
<i>FIGURE 20 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR BLOOD DISORDERS AND SKIN DISEASES, BY REGION, 2014-2021 (\$ MILLIONS)</i>	116
GROWTH HORMONE DISORDER, ENZYME DISORDER AND FERTILITY DISORDER	116
Market Overview	117
Market Revenue	118
<i>TABLE 54 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR GROWTH HORMONE, ENZYME AND FERTILITY DISORDERS, BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	118
<i>FIGURE 21 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR GROWTH HORMONE, ENZYME AND FERTILITY DISORDERS, BY REGION, 2014-2021 (\$ MILLIONS)</i>	118
OTHERS	119
Multiple Sclerosis	119
Hepatitis	119
Crohn's Disease	120

TOPIC	PAGE NO.
Influenza	120
Pneumonia	121
Cystic Fibrosis	121
Asthma	121
Meningitis	121
Rheumatoid Arthritis	121
Market Overview	122
Market Revenue	123
<i>TABLE 55 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR OTHER DISEASES, BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	123
<i>FIGURE 22 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR OTHER DISEASES, BY REGION, 2014-2021 (\$ MILLIONS)</i>	123
CHAPTER 9 PATENT ANALYSIS	126
PATENTS BY YEAR	126
<i>TABLE 56 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY YEAR, 2014-JUNE 2016</i>	127
<i>FIGURE 23 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY YEAR, 2014-JUNE 2016</i>	127
PATENTS BY TYPE	127
<i>TABLE 57 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY TYPE, 2014-JUNE 2016</i>	128
<i>FIGURE 24 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY TYPE, 2014-JUNE 2016</i>	128
PATENTS BY COMPANY	128
<i>TABLE 58 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY COMPANY, 2014-JUNE 2016</i>	129
PATENTS BY COUNTRY	132
<i>TABLE 59 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY COUNTRY,* 2014-JUNE 2016</i>	132
<i>TABLE 60 PATENT SHARES FOR MANUFACTURING OF PROTEIN DRUGS, BY COUNTRY, 2014-JUNE 2016 (NO./%)</i>	133
PATENTS BY ASSIGNEE	134
<i>TABLE 61 NUMBER OF PATENTS, BY ASSIGNEE, 2014-JUNE 2016</i>	134
<i>FIGURE 25 NUMBER OF PATENTS, BY ASSIGNEE, 2014-JUNE 2016</i>	134
CHAPTER 10 CURRENT SITUATION	137
FACTORS AFFECTING BIOENGINEERED PROTEIN DRUGS	137
INCREASING PREVALENCE OF CHRONIC DISEASES	137
GROWING AGING POPULATION	137
LIFESTYLE CHANGES	138
AWARENESS AND EDUCATION	138
ADVANCEMENTS IN MANUFACTURING TECHNOLOGIES	138
PRICE CONTROLS	138
REGULATORY PRESSURES	139
LICENSING AGREEMENTS	139
MERGERS AND ACQUISITIONS	140
ENTRY OF FOLLOW-ON-BIOLOGICS/BIOSIMILARS	140

TOPIC	PAGE NO.
CHAPTER 11 COMPANY PROFILES	142
ABBVIE INC.	142
ACTAVIS INC.	142
ALEXION PHARMACEUTICALS	142
ALLERGAN PLC.	143
AMGEN INC	143
APOTEX INC.	144
BAXALTA INC	144
BAYER HEALTHCARE PHARMACEUTICALS	145
BIOMARIN PHARMACEUTICAL INC.	145
BIOGEN IDEC	145
BIOTEST PHARMACEUTICALS CORPORATION	146
BRISTOL-MYERS SQUIBB	146
CSL LIMITED	147
ELI LILLY	147
FRESENIUS KABI USA	148
GLAXOSMITHKLINE	148
GRIFOLS USA LLC.	148
HOFFMAN-LA ROCHE	149
HOSPIRA INC.	149
JOHNSON & JOHNSON	149
MEDIMMUNE LLC	150
MERCK & CO, INC	150
MYLAN INC.	151
NOVARTIS AG	151
NOVO NORDISK AG	152
OCTAPHARMA AG	152
PFIZER INC	153
SANOFI INC	153
SEATTLE GENETICS INC.	154
SPECTRUM PHARMACEUTICALS INC.	154
TAKEDA PHARMACEUTICAL U.S.A., INC	154
UCB COMPANY	155
CHAPTER 12 APPENDIX I-ABBREVIATIONS	157

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY REGION, THROUGH 2021 (\$ MILLIONS)	8
TABLE 1 BIOENGINEERED PROTEIN DRUGS VS. CHEMICALLY SYNTHESIZED DRUGS	12
TABLE 2 EVOLUTION OF BIOENGINEERED PROTEIN DRUGS	13
TABLE 3 PROTEIN DRUGS MADE BY FRACTIONATION	16
TABLE 4 THERAPETIC DRUGS PRODUCED BY MICROBIAL FERMENTATION	17
TABLE 5 PROTEIN DRUGS PRODUCED BY TRANSGENIC ANIMALS, PLANTS AND MICROORGANISMS	18
TABLE 6 PROTEIN DRUGS MADE BY MAMMALIAN CELL CULTURE	19
TABLE 7 ROUTES OF DRUG DELIVERY	21
TABLE 8 NEW APPROVALS OF MONOCLONAL ANTIBODIES (FROM 2014-MAY 2016)	32
TABLE 9 NEW APPROVALS OF CYTOKINES (FROM 2014-2015)*	34
TABLE 10 NEW APPROVALS IN VACCINES (FROM 2014-MAY 2016)	34
TABLE 11 NEW APPROVALS IN PEPTIDE HORMONES (FROM 2014-2015)*	35
TABLE 12 NEW APPROVALS IN THERAPEUTIC ENZYMES (FROM 2014-2015)*	36
TABLE 13 NEW APPROVALS IN BLOOD PRODUCTS (FROM 2014-MAY 2016)	36
TABLE 14 NEW APPROVALS IN PEPTIDE ANTIBIOTICS (FROM 2014-2015)*	37
TABLE 15 RECALLS (FROM 2014-2015)*	38
TABLE 16 SAFETY ALERTS (FROM 2014-2015)*	39
TABLE 17 PIPELINE PRODUCTS OF MONOCLONAL ANTIBODIES	42
TABLE 18 PIPELINE PRODUCTS OF VACCINES	48
TABLE 19 PIPELINE PRODUCTS OF CYTOKINES	50
TABLE 20 PIPELINE PRODUCTS OF PEPTIDE HORMONES	51
TABLE 21 PIPELINES PRODUCTS OF PEPTIDE ANTIBIOTICS	52
TABLE 22 PIPELINE PRODUCTS OF THERAPUETIC ENZYMES	53
TABLE 23 PIPELINE PRODUCTS OF BLOOD PRODUCTS	53
TABLE 24 MERGERS AND ACQUISITIONS OF TOP PHARMACEUTICAL COMPANIES	54
TABLE 25 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, THROUGH 2021 (\$ MILLIONS)	60
TABLE 26 GLOBAL MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, 2015 (%)	61
TABLE 27 GLOBAL MARKET FOR PEPTIDE HORMONES, BY REGION, THROUGH 2021 (\$ MILLIONS)	64
TABLE 28 GLOBAL MARKET FOR VACCINES, BY REGION, THROUGH 2021 (\$ MILLIONS)	67
TABLE 29 GLOBAL MARKET FOR THERAPEUTIC ENZYMES, BY REGION, THROUGH 2021 (\$ MILLIONS)	69
TABLE 30 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, THROUGH 2021 (\$ MILLIONS)	72
TABLE 31 GLOBAL MARKET FOR CYTOKINES, BY REGION, THROUGH 2021 (\$ MILLIONS)	74
TABLE 32 GLOBAL MARKET FOR BLOOD FACTORS AND PEPTIDE ANTIBIOTICS, BY REGION, THROUGH 2021 (\$ MILLIONS)	77
TABLE 33 LEADING MANUFACTURERS/SUPPLIERS OF PEPTIDE HORMONES, 2015	79
TABLE 34 GLOBAL MARKET SHARE OF MANUFACTURERS AND SUPPLIERS FOR BIOENGINEERED PEPTIDE HORMONES, 2015 (%)	81
TABLE 35 LEADING MANUFACTURERS/SUPPLIERS OF VACCINES, 2015	82
TABLE 36 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR VACCINES, 2015 (%)	86

TABLE HEADING	PAGE NO.
TABLE 37 LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC ENZYMES, 2015	86
TABLE 38 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR THERAPEUTIC ENZYMES, 2015 (%)	88
TABLE 39 LEADING MANUFACTURERS/SUPPLIERS OF MONOCLONAL ANTIBODIES, 2015	89
TABLE 40 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR MONOCLONAL ANTIBODIES, 2015 (%)	90
TABLE 41 LEADING MANUFACTURERS/SUPPLIERS OF CYTOKINES, 2015	91
TABLE 42 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR CYTOKINE, 2015 (%)	92
TABLE 43 LEADING MANUFACTURERS/SUPPLIERS OF RECOMBINANT BLOOD PRODUCTS, 2015	93
TABLE 44 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR RECOMBINANT BLOOD PRODUCTS, 2015 (%)	94
TABLE 45 LEADING MANUFACTURERS/SUPPLIERS OF PEPTIDE ANTIBIOTICS, 2015	95
TABLE 46 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR PEPTIDE ANTIBIOTICS, 2015 (%)	96
TABLE 47 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, THROUGH 2021 (\$ MILLIONS)	101
TABLE 48 GLOBAL MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, 2015	102
TABLE 49 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR DIABETES, BY REGION, THROUGH 2021 (\$ MILLIONS)	105
TABLE 50 VARIOUS CANCER TYPES DEPENDING ON THE TISSUE OF ORIGIN	107
TABLE 51 CATEGORIES OF CANCER	107
TABLE 52 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR CANCER, BY REGION, THROUGH 2021 (\$ MILLIONS)	109
TABLE 53 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR BLOOD DISORDERS AND SKIN DISEASES, BY REGION, THROUGH 2021 (\$ MILLIONS)	116
TABLE 54 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR GROWTH HORMONE, ENZYME AND FERTILITY DISORDERS, BY REGION, THROUGH 2021 (\$ MILLIONS)	118
TABLE 55 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR OTHER DISEASES, BY REGION, THROUGH 2021 (\$ MILLIONS)	123
TABLE 56 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY YEAR, 2014-JUNE 2016	127
TABLE 57 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY TYPE, 2014-JUNE 2016	128
TABLE 58 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY COMPANY, 2014-JUNE 2016	129
TABLE 59 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY COUNTRY,* 2014-JUNE 2016	132
TABLE 60 PATENT SHARES FOR MANUFACTURING OF PROTEIN DRUGS, BY COUNTRY, 2014-JUNE 2016 (NO./%)	133
TABLE 61 NUMBER OF PATENTS, BY ASSIGNEE, 2014-JUNE 2016	134

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY REGION, 2014-2021 (\$ MILLIONS)	8
FIGURE 1 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, 2014-2021 (\$ MILLIONS)	60
FIGURE 2 GLOBAL MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, 2015 (%)	61
FIGURE 3 GLOBAL MARKET FOR PEPTIDE HORMONES, BY REGION, 2014-2021 (\$ MILLIONS)	64
FIGURE 4 GLOBAL MARKET FOR VACCINES, BY REGION, 2014-2021 (\$ MILLIONS)	67
FIGURE 5 GLOBAL MARKET FOR THERAPEUTIC ENZYMES, BY REGION, 2014-2021 (\$ MILLIONS)	70
FIGURE 6 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2014-2021 (\$ MILLIONS)	72
FIGURE 7 GLOBAL MARKET FOR CYTOKINES, BY REGION, 2014-2021 (\$ MILLIONS)	74
FIGURE 8 GLOBAL MARKET FOR BLOOD FACTORS AND PEPTIDE ANTIBIOTICS, BY REGION, 2014-2021 (\$ MILLIONS)	77
FIGURE 9 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR BIOENGINEERED PEPTIDE HORMONES, 2015 (%)	82
FIGURE 10 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR VACCINES, 2015 (%)	86
FIGURE 11 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR THERAPEUTIC ENZYMES, 2015 (%)	88
FIGURE 12 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR MONOCLONAL ANTIBODIES, 2015 (%)	91
FIGURE 13 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR CYTOKINE, 2015 (%)	92
FIGURE 14 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR RECOMBINANT BLOOD PRODUCTS, 2015 (%)	94
FIGURE 15 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR PEPTIDE ANTIBIOTICS, 2015 (%)	96
FIGURE 16 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, 2014-2021 (\$ MILLIONS)	101
FIGURE 17 GLOBAL MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, 2015 (%)	102
FIGURE 18 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR DIABETES, BY REGION, 2014-2021 (\$ MILLIONS)	105
FIGURE 19 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR CANCER, BY REGION, 2014-2021 (\$ MILLIONS)	109
FIGURE 20 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR BLOOD DISORDERS AND SKIN DISEASES, BY REGION, 2014-2021 (\$ MILLIONS)	116
FIGURE 21 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR GROWTH HORMONE, ENZYME AND FERTILITY DISORDERS, BY REGION, 2014-2021 (\$ MILLIONS)	118
FIGURE 22 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS FOR OTHER DISEASES, BY REGION, 2014-2021 (\$ MILLIONS)	123
FIGURE 23 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY YEAR, 2014-JUNE 2016	127
FIGURE 24 NUMBER OF PATENTS GRANTED IN MANUFACTURING OF PROTEIN DRUGS, BY TYPE, 2014-JUNE 2016	128
FIGURE 25 NUMBER OF PATENTS, BY ASSIGNEE, 2014-JUNE 2016	134